Aimmtherapeutics

AIMM therapeutics B.V. was established in 2004 with the goal to develop therapeutic and prophylactic human monoclonal antibodies. AIMM capitalizes on a proprietary technology to immortalize human B cells enabling identification of human antibodies of high clinical value.

We have generated a series of monoclonal antibodies specific for several pathogenic viruses and bacteria. The current pipeline includes antibodies against respiratory syncytial virus, influenza virus and staphylococcus aureus

AIMM has received financing from its principal investor, the AMC and from the Life Science Fund Amsterdam